78510-27-7

Basic information

• Product Name: sodium 1-amino-4-o-methoxyanilino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonate
• Synonyms: sodium 1-amino-4-o-methoxyanilino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonate;1-Amino-2-(sodiooxysulfonyl)-4-(2-methoxyphenylamino)-9,10-anthraquinone;1-Amino-9,10-dihydro-4-[(2-methoxyphenyl)amino]-9,10-dioxo-2-anthracenesulfonic acid sodium salt;Sodium 1-amino-4-o-methoxyanilino-9,10-dihydro-9,10-dioxoanthracene-2-sulfonate
• CAS NO: 78510-27-7
• Molecular Formula: C₂₁H₁₅N₂O₆S*Na
• Molecular Weight: 446.40837
• EINECS: 278-930-3
• Mol File: 78510-27-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 680.9°C at 760 mmHg
• Flash Point: 365.6°C
• Appearance: /
• Vapor Pressure: 2.15E-18mmHg at 25°C
• CAS DataBase Reference: sodium 1-amino-4-o-methoxyanilino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonate(CAS DataBase Reference)
• NIST Chemistry Reference: sodium 1-amino-4-o-methoxyanilino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonate(78510-27-7)
• EPA Substance Registry System: sodium 1-amino-4-o-methoxyanilino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonate(78510-27-7)

Safety Data

• Hazardous Substances Data: 78510-27-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C21H16N2O6S.Na/c1-28-13-8-6-12(7-9-13)23-29-30(26,27)17-11-10-16-18(19(17)22)21(25)15-5-3-2-4-14(15)20(16)24;/h2-11,23H,22H2,1H3;/q;+1

Upstream product

• 6258-06-6 sodium 1-amino-4-bromoanthraquinone-2-sulfonate 
• 90-04-0 2-methoxy-phenylamine 

Downstream Products

• 1415237-71-6 4-(2-methoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid 

Relevant articles and documents

Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor

P2Y4 is a Gq protein-coupled receptor activated by uridine-5′-triphosphate (UTP), which is widely expressed in the body, e.g., in intestine, heart, and brain. No selective P2Y4 receptor antagonist has been described so far. Therefore, we developed and optimized P2Y4 receptor antagonists based on an anthraquinone scaffold. Potency was assessed by a fluorescence-based assay measuring inhibition of UTP-induced intracellular calcium release in 1321N1 astrocytoma cells stably transfected with the human P2Y4 receptor. The most potent compound of the present series, sodium 1-amino-4-[4-(2,4-dimethylphenylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-16133, 61) exhibited an IC50 value of 233 nM, selectivity versus other P2Y receptor subtypes, and is thought to act as an allosteric antagonist. A receptor homology model was built and docking studies were performed to analyze ligand-receptor interactions. Compound 64 (PSB-1699, sodium 1-amino-4-[4-(3-pyridin-3-ylmethylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate) represents the most selective P2Y4 receptor antagonist known to date. Compounds 61 and 64 are therefore anticipated to become useful tools for studying this scarcely investigated receptor.

Anthraquinone compounds and their uses

This invention relates to compounds comprising a substituted or unsubstituted anthraquinone, or a salt or isomer thereof, for use in treating a disorder caused by or associated with dysfunctional ion channel activity; for example, BK Channel activity. The compounds of the present invention find utility in the treatment such as urinary incontinence, irritable bowel syndrome, diabetes and arterial hypertension, cardiovascular diseases including myocardial infarction, erectile dysfunction and airway constriction.

Novel P2Y12 receptor antagonists

The present invention relates to compounds of Formula I, in which A and B are independently CH2, O, S, NH, C=O, C=NH, C=S or C=N-OH; X is NH, O, S, C=O or CH2 and R1-R5 are as defined in claim 1, which are P2Y12 receptor antagonists and useful for treating, alleviating and/or preventing diseases and disorders related to P2Y12 receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The present invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviation, prevention and/or treatment of diseases and disorders, especially the use as antithrombotic agents for inhibiting platelet aggregation.